Inovio demonstrates 80% 6-month progression-free survival in phase 2 glioblastoma multiforme (gbm) study with ino-5401 in combination with pd-1 inhibitor libtayo (cemiplimab)

Inovio demonstrates 80% 6-month progression-free survival in phase 2 glioblastoma multiforme (gbm) study with ino-5401 in combination with pd-1 inhibitor libtayo® (cemiplimab).inovio pharmaceuticals - announced positive interim results from co's phase 2 study of newly diagnosed glioblastoma multiforme.inovio pharmaceuticals - immunotherapy combination with a pd-1 checkpoint inhibitor exhibited supportive safety, tolerability, immunogenicity data.
INO Ratings Summary
INO Quant Ranking